Clement Anfray
Overview
Explore the profile of Clement Anfray including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
376
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amedlous A, Helaine C, Dalena F, Anfray C, Menard T, Blanchard I, et al.
ACS Appl Mater Interfaces
. 2025 Jan;
17(5):8003-8016.
PMID: 39851270
Tumor hypoxia significantly limits the effectiveness of radiotherapy, as oxygen is crucial for producing cancer-killing reactive oxygen species. To address this, we synthesized nanosized faujasite (PBS-Na-FAU) zeolite crystals using clinical-grade...
2.
Anfray C, Varela C, Ummarino A, Maeda A, Sironi M, Gandoy S, et al.
Front Immunol
. 2024 Jan;
14:1334800.
PMID: 38259462
Background: In the tumor microenvironment (TME), tumor-associated macrophages (TAMs) play a key immunosuppressive role that limits the ability of the immune system to fight cancer. Toll-like receptors (TLRs) ligands, such...
3.
Ummarino A, Pensado-Lopez A, Migliore R, Alcaide-Ruggiero L, Cala N, Caputo M, et al.
Eur J Immunol
. 2023 Sep;
53(12):e2350507.
PMID: 37713238
Osteoarthritis (OA) is characterized by an abundance of inflammatory M1-like macrophages damaging local tissues. The search for new potential drugs for OA suffers from the lack of appropriate methods of...
4.
Digifico E, Erreni M, Mannarino L, Marchini S, Ummarino A, Anfray C, et al.
Front Immunol
. 2023 Jul;
14:1116430.
PMID: 37398648
Background: Malignant Pleural Mesothelioma (MPM) is an aggressive cancer of the mesothelial lining associated with exposure to airborne non-degradable asbestos fibers. Its poor response to currently available treatments prompted us...
5.
Anfray C, Ummarino A, Calvo A, Allavena P, Andon F
Methods Mol Biol
. 2022 Dec;
2614:93-108.
PMID: 36587121
In most solid cancers, tumor-associated macrophages (TAMs) infiltrating the tumor microenvironment (TME) represent a major population of immunosuppressive cells. This correlates with poor prognosis and resistance to antitumoral therapies, including...
6.
Ummarino A, Anfray C, Maeda A, Andon F, Allavena P
Methods Mol Biol
. 2022 Dec;
2614:81-91.
PMID: 36587120
Tumor-associated macrophages (TAMs) play a key immunosuppressive role that limits the ability of the immune system to fight cancer and hinder the anti-tumoral efficacy of most treatments currently applied in...
7.
Fernandez-Marino I, Anfray C, Crecente-Campo J, Maeda A, Ummarino A, Teijeiro-Valino C, et al.
Drug Deliv Transl Res
. 2022 Dec;
13(7):1896-1911.
PMID: 36472784
Tumor-associated macrophages (TAMs), a class of immune cells that play a key role in tumor immunosuppression, are recognized as important targets to improve cancer prognosis and treatment. Consequently, the engineering...
8.
Andon F, Leon S, Ummarino A, Redin E, Allavena P, Serrano D, et al.
Biomedicines
. 2022 Jul;
10(7).
PMID: 35884895
Toll-like receptors (TLRs) are natural initial triggers of innate and adaptive immune responses. With the advent of cancer immunotherapy, nucleic acids engineered as ligands of endosomal TLRs have been investigated...
9.
Anfray C, Mainini F, Digifico E, Maeda A, Sironi M, Erreni M, et al.
J Immunother Cancer
. 2021 Sep;
9(9).
PMID: 34531246
Background: Tumor-associated macrophages (TAMs) play a key immunosuppressive role that limits the ability of the immune system to fight cancer and hinder the antitumoral efficacy of most treatments currently applied...
10.
Reimunde P, Pensado-Lopez A, Carreira Crende M, Lombao Iglesias V, Sanchez L, Torrecilla-Parra M, et al.
Cancers (Basel)
. 2021 Apr;
13(5).
PMID: 33802571
Glioblastoma (GBM) is the most common of all brain malignant tumors; it displays a median survival of 14.6 months with current complete standard treatment. High heterogeneity, aggressive and invasive behavior,...